A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo

NCT06905873 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-11-20

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.

Conditions

  • Vitiligo

Interventions

DRUG

FB102

Route of administration- Intravenous (IV)

DRUG

Placebo

Route of administration- Intravenous (IV)

Sponsors & Collaborators

  • Forte Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-25
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06905873 on ClinicalTrials.gov